Isomorphic Labs Secures $2.1 Billion in Record-Breaking Series B Funding to Advance AI-Driven Drug Discovery

This article is based on publicly available information and is intended solely for informational exchange. It does not constitute any investment advice.

On May 12, 2026, London, Isomorphic Labs, an Alphabet subsidiary under Google's parent company that focuses on AI-driven drug discovery, announced the completion of its $2.1 billion Series B financing round, approximately RMB 14.3 billion.

Thrive Capital led the investment, with Alphabet and GV following. New investors include Abu Dhabi's MGX, Singapore's Temasek, and the UK Sovereign AI Fund. Just a year ago, the Series A round was only 600 million US dollars, while the Series B round has more than tripled, setting a record for the largest single round of financing in AI pharmaceuticals.

Isomorphic Labs was spun off from Google DeepMind in 2021, with CEO Demis Hassabis also leading DeepMind.

The foundation of this company is AlphaFold, a protein structure prediction model that emerged in 2020 and was hailed for solving the "50-year biological problem" in one fell swoop. In 2024, Hassabis and his colleague John Jumper were awarded the Nobel Prize in Chemistry for this achievement.

The Nobel Prize is the ultimate seal of approval in the scientific community, while this $21 billion represents the same vote cast by capital, with a much larger denomination.

This money will be spent in three directions: further development of the AI drug design engine IsoDDE, acceleration of the internal preclinical pipeline, and expansion of the AI, engineering, and drug design teams worldwide. Translated into one sentence: Pouring money for speed, betting on an unproven future.

01

From Auxiliary Tools to Infrastructure

AI Enters Drug Discovery, Not Starting in 2026.

As early as the 1980s, computer-aided drug design had become a routine tool for scientists. However, CADD relies on human-prescribed rules, and its capabilities have always been limited. The change brought by AI is not to replace it but to redefine the role of "computation" in drug discovery.

Around 2010, machine learning began to infiltrate drug discovery, mainly focusing on virtual screening, ADMET prediction, and other aspects. In 2016, deep learning pushed the capabilities of molecular generation and activity prediction to new heights.

The real qualitative change occurred after the advent of AlphaFold: it demonstrated that deep learning could solve the most challenging structure prediction problems in biology with accuracy approaching experimental levels. The first hurdle in drug discovery—understanding the 3D structure of target proteins—was overcome by AI at an extremely low cost and with incredible speed.

Since then, the industry has accelerated its evolution.

In early 2026, Eli Lilly and NVIDIA announced a $1 billion investment to establish a joint AI drug discovery laboratory. On April 16, 2026, OpenAI launched GPT-Rosalind, specifically designed for biology and drug discovery, directly entering the pharmaceutical arena.

This is a typical competition for the new-generation infrastructure in the biopharmaceutical industry. By 2026, AI-driven drug discovery has crossed the line from being an "optional auxiliary tool" to becoming an "essential core productivity."

02

IsoDDE's Ambitions and Blind Spots

AlphaFold solves "static structure prediction": given an amino acid sequence, it outputs a three-dimensional structure. However, drug design requires much more than this. Molecules not only need to bind, but also bind strongly; they need to be effective on the target and harmless to "off-targets."

AlphaFold can tackle the first piece, but the subsequent ones are out of its range. Isomorphic Labs' response is IsoDDE: a set of drug design engines.

This system predicts protein-ligand structures with more than twice the accuracy of AlphaFold 3 in challenging benchmark tests. It can predict binding affinity, the strength of drug-target binding, with an accuracy comparable to the previously gold-standard physical simulation methods, while being several orders of magnitude faster.

It can also identify drug-binding pockets solely based on amino acid sequences, including hidden pockets that the scientific community has failed to detect for over a decade. In the first half of the drug discovery process—"target identification, molecule design, and activity prediction"—Isomorphic Labs aims to run the entire process within a single system.

But the technical bottleneck is equally glaring.

Currently, the generalization ability of AI in novel protein systems is still insufficient. Once encountering biological systems unseen in the training data, the prediction accuracy significantly declines. The physical rules governing protein-ligand interactions are extremely complex, and AI models have yet to fully capture their dynamic characteristics.

More fatally, all AI models are limited by the bias in training data – the known drug-target interaction data is severely skewed, and a large number of potential targets lack high-quality annotations. No matter how good the model is, it’s like feeding it the same textbook with missing pages.

03

"Drug Discovery = A Computable Engineering Problem"

$21 billion is an extremely expensive bet.

As of May 2026, there is still no AI-designed drug that has truly entered the clinical stage globally, let alone been successfully marketed.

Even Isomorphic Labs itself has not yet advanced any AI-designed molecules into clinical trials.

Hassabis once predicted in 2025 that "a candidate drug would enter clinical trials by the end of the year," later revising it to "preclinical research." According to a Bloomberg report, during the World Economic Forum in Davos this January, he had postponed the timeline for the first clinical trial from the end of 2025 to the end of 2026. This is not a failure, but it is indeed recalibrating market expectations: the last mile of AI-driven drug discovery is longer than everyone initially anticipated.

The situation of other players in the industry is even more disheartening.

Recursion Pharmaceuticals has fallen nearly 90% from its 2021 IPO high, with a market value of approximately $1.9 to $2 billion, almost returning to the valuation of a mid-sized biotech company. NVIDIA fully divested its holdings of RXRX shares by February 2026. BenevolentAI in the UK announced at the end of 2024 that it would delist from the Euronext Amsterdam exchange and implement large-scale layoffs and cost reductions.

After the high bubble, when will the high return appear? So far, no one has the answer.

$2.1 billion can do a lot. It can cover the majority of expenses for an entire clinical development chain, or directly acquire several mid-sized biotech companies. But Isomorphic Labs has chosen to bet all of this money on an extremely costly foundational hypothesis: drug discovery can be transformed into a computable engineering problem.

The subtext is: As long as the model is good enough, the data is sufficient, and the computing power is strong enough, designing effective drugs can be as automated as designing chips.

If this hypothesis holds true, 21 billion yuan is merely the price of admission. If it doesn't, it will be the most expensive philosophical trial-and-error in the AI era.

04

Rush in, or be left outside

If Isomorphic Labs succeeds, drug discovery will shift from "screening" to "design," marking a great paradigm revolution.

The average cycle of current drug development is 12 to 15 years, with an average cost exceeding 2 billion US dollars. 90% of candidate drugs fail in clinical trials. If AI can improve R&D efficiency by even a few percentage points, the annual savings for the global industry could reach tens of billions of US dollars.

But Isomorphic Labs has chosen a path that is completely opposite to that of traditional pharmaceutical companies.

Traditional pharmaceutical companies rely on scientists' experience and massive experiments for drug discovery, which is labor-intensive work in wet labs; Isomorphic Labs’ methodology is a fully digital “design-predict-validate” loop.

AI designs molecules in silicon-based space, predicting activity, toxicity, and pharmacokinetic properties, selecting the best candidates, and then validating them with a small number of wet lab experiments. If this pathway can be successfully executed, the "wet experimentation" part of drug discovery will be systematically compressed. What Hassabis refers to as "AI-first drug design" essentially lies in this.

The capital market sees the possibility, but history never easily yields the answer.

A century ago, chemist Paul Ehrlich introduced the concept of the "magic bullet," heralding the era of precision-targeted drugs—an era that took three-quarters of a century to truly mature. Thirty years ago, gene therapy sparked a frenzy of capital investment, only for a single serious adverse event to set the industry back a decade. AI drug discovery has just passed its initial phase of hype, and there remains a long journey before achieving large-scale clinical validation.

This $2.1 billion is a bet on an unproven hypothesis: that AI can evolve from "predicting protein structures" all the way to "designing every effective drug"; it’s a bet that the complexity of drug discovery can be reduced to a computable engineering problem.

In the history of science, such high-stakes gambles have paid off before — the Human Genome Project ultimately ushered in a golden age for the entire biotechnology industry. But they have also failed, with several AI winters burying countless ambitious laboratories. In the end, what determines the outcome is not the scale of funding, but the efficacy data from the real world.

Isomorphic Labs is betting that a paradigm revolution in drug discovery is underway. $2.1 billion is the price of admission to this revolution.

For China's innovative pharmaceutical companies, the truly noteworthy aspect of this financing is not the amount, but the emergence of a completely different R&D philosophy: as the world's top AI labs begin to apply engineering thinking to solve drug discovery, those who are still using linear thinking to catch up will face not competition, but generational obsolescence.

The window of paradigm revolution opens only once; rush in, or be left outside. Time waits for no one.

       Title: $2 billion, AI Drug Discovery Just Secured the Largest Funding Round